TScan Therapeutics, Inc.
TCRX · XNASCIK 1783328fmd_0HHMRXTCNTRC4DY4RJCEVWKMY1Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 1 | 10 | 14 | 21 | 3 | 10 |
| Research and development | 21 | 45 | 60 | 88 | 107 | 114 |
| Total operating expenses | 27 | 59 | 80 | 115 | 138 | 146 |
| Operating income | (26) | (49) | (67) | (93) | (135) | (136) |
| Interest expense | – | – | 1 | 4 | 4 | 3 |
| Interest and investment income | – | 0 | 2 | 8 | 12 | 9 |
| Other non-operating income (expense) | – | 0 | 0 | 4 | 7 | 6 |
| Income tax expense | – | – | – | – | – | 0 |
| Net income | (26) | (49) | (66) | (89) | (127) | (130) |